1. [CASE 1 — QUESTION 1]
A 39-year-old man (P.R.) who emigrated from a region endemic for Taenia solium presents with two new-onset focal seizures. MRI shows three viable parenchymal cysts, one with a visible scolex, and mild surrounding enhancement; there are no calcified lesions. He has no visual or cardiac complaints. The neurology team plans antiparasitic therapy and asks how to construct the regimen. Which antiparasitic backbone and adjunct combination is most appropriate for viable parenchymal neurocysticercosis?
A) Praziquantel monotherapy without corticosteroid, to preserve praziquantel cerebrospinal fluid levels
B) Albendazole as the antiparasitic backbone given together with a corticosteroid to control the inflammatory response to dying cysts, plus an antiepileptic for seizure control
C) No antiparasitic therapy, because viable parenchymal cysts never benefit from treatment
D) Diethylcarbamazine plus a corticosteroid, since diethylcarbamazine has the best central nervous system penetration
E) Triclabendazole plus a corticosteroid, since tissue cestodes respond preferentially to triclabendazole
ANSWER: B
Rationale:
Viable parenchymal neurocysticercosis cysts benefit from antiparasitic therapy, and killing them incites inflammation that mandates a concurrent corticosteroid; an antiepileptic addresses the seizures. Albendazole is the preferred backbone because its central nervous system penetration is preserved despite corticosteroid co-administration, whereas the corticosteroid lowers praziquantel cerebrospinal fluid levels.
Option A: Option A is incorrect; omitting the corticosteroid while killing viable cysts is unsafe, and praziquantel alone is the wrong central choice under steroid co-treatment.
Option C: Option C is incorrect; viable cysts do benefit from treatment, unlike calcified-only cysts.
Option D: Option D is incorrect; diethylcarbamazine is a filarial agent with no role in neurocysticercosis.
Option E: Option E is incorrect; triclabendazole is the Fasciola agent and is not used for neurocysticercosis.
2. [CASE 1 — QUESTION 2]
Continuing with the same patient. A colleague asks why albendazole, rather than praziquantel, is preferred as the antiparasitic specifically because a corticosteroid is being co-administered. Which pharmacokinetic interaction best justifies the choice?
A) Corticosteroids raise praziquantel cerebrospinal fluid levels, making it too toxic to use centrally
B) Corticosteroids abolish albendazole absorption, forcing the use of praziquantel
C) Corticosteroids and praziquantel form an inactive chelate in the cerebrospinal fluid
D) Corticosteroids reduce praziquantel cerebrospinal fluid concentrations, whereas albendazole's central nervous system penetration is not meaningfully reduced by concurrent corticosteroid, so albendazole maintains effective central exposure
E) Albendazole and corticosteroids share identical central transport, making the choice arbitrary
ANSWER: D
Rationale:
Concurrent corticosteroids reduce praziquantel cerebrospinal fluid concentrations, undermining its central efficacy, whereas albendazole's central penetration is not meaningfully reduced by corticosteroids. Albendazole therefore maintains effective central exposure during the steroid co-treatment that neurocysticercosis requires, justifying its preference.
Option A: Option A is incorrect; corticosteroids lower, not raise, praziquantel central levels.
Option B: Option B is incorrect; corticosteroids do not abolish albendazole absorption.
Option C: Option C is incorrect; there is no inactive corticosteroid-praziquantel chelate in the cerebrospinal fluid.
Option E: Option E is incorrect; albendazole and corticosteroids do not share identical central transport, and the choice is not arbitrary.
3. [CASE 1 — QUESTION 3]
Continuing with the same patient. Suppose that instead of viable cysts, his MRI had shown only small calcified lesions with no scolex and no enhancement. How should the parasitic component be managed in that scenario?
A) Do not give antiparasitic therapy, because calcified lesions are dead and gain no benefit from it; manage seizures with antiepileptic therapy and avoid the needless inflammatory risk of treating dead cysts
B) Give a prolonged high-dose albendazole course to dissolve the calcified lesions
C) Give albendazole plus praziquantel to ensure complete destruction of the calcified cysts
D) Administer praziquantel monotherapy, since calcified cysts respond preferentially to it
E) Begin diethylcarbamazine to penetrate and clear the calcified foci
ANSWER: A
Rationale:
Calcified neurocysticercosis lesions are dead, and antiparasitic drugs act only on living parasites; treating calcified-only disease offers no benefit while adding the risk of inflammation around the lesions. The correct approach is to withhold antiparasitic therapy and manage seizures with antiepileptic treatment.
Option B: Option B is incorrect; albendazole cannot dissolve dead calcified lesions and adds only risk.
Option C: Option C is incorrect; combination antiparasitic therapy of dead cysts provides no benefit.
Option D: Option D is incorrect; calcified cysts do not respond to praziquantel or any antiparasitic.
Option E: Option E is incorrect; diethylcarbamazine is a filarial agent with no role here, and dead cysts would not benefit regardless.
4. [CASE 1 — QUESTION 4]
Continuing with the same patient. Before initiating antiparasitic therapy for his viable cysts, which pre-treatment evaluation is most important to avoid precipitating a sight-threatening complication?
A) A coagulation panel, since albendazole routinely causes major bleeding
B) An exercise stress test, since antihelminthics commonly provoke myocardial ischemia
C) Pulmonary function testing, since albendazole causes acute bronchospasm
D) A serum drug-level assay for albendazole before dosing, since therapy cannot begin without it
E) Evaluation for ocular (and high-burden intraventricular) cysticercosis, because antiparasitic-induced inflammation around a cyst within the eye can threaten vision, so ocular involvement must be identified before starting therapy
ANSWER: E
Rationale:
Antiparasitic therapy kills cysts and provokes local inflammation; if a cyst lies within the eye, that inflammatory reaction can threaten vision, so ocular cysticercosis must be identified before treatment (intraventricular disease similarly changes management). Screening for these high-risk locations is the key pre-treatment step.
Option A: Option A is incorrect; albendazole does not routinely cause major bleeding requiring a pre-treatment coagulation panel.
Option B: Option B is incorrect; antihelminthics do not commonly provoke myocardial ischemia, so a stress test is not indicated.
Option C: Option C is incorrect; albendazole is not a typical cause of acute bronchospasm warranting pulmonary function testing.
Option D: Option D is incorrect; routine pre-dose serum albendazole-level assays are not required to begin therapy and would not prevent a sight-threatening complication.
5. [CASE 2 — QUESTION 1]
A 44-year-old sheep farmer (S.D.) is found on imaging to have a 9-centimeter hepatic cyst with daughter cysts, classified as an active WHO stage CE2 cystic echinococcosis lesion caused by Echinococcus granulosus. She is otherwise well. The hepatobiliary team is deciding on an overall approach. Which management principle correctly matches this active cyst to its options?
A) Active CE2 cysts are inactive and should simply be observed without any intervention or drug therapy
B) Active CE2 cysts require lifelong diethylcarbamazine as the sole therapy
C) Active cysts (CE1 and CE2) are candidates for PAIR (puncture-aspiration-injection-reaspiration) or surgical resection, with perioperative albendazole cover, because the WHO cyst stage guides whether intervention plus drug therapy is indicated
D) Active CE2 cysts should be treated with praziquantel alone, since praziquantel is the agent of choice for all cestode disease
E) Active CE2 cysts mandate immediate triclabendazole, the agent of choice for echinococcosis
ANSWER: C
Rationale:
The WHO classification of echinococcal cyst stages guides management. Active cysts (CE1 and CE2) are candidates for PAIR or surgical resection with perioperative albendazole cover, integrating procedural and pharmacological therapy.
Option A: Option A is incorrect; CE2 is an active, not inactive, stage and is not simply observed.
Option B: Option B is incorrect; diethylcarbamazine is a filarial agent with no role in echinococcosis.
Option D: Option D is incorrect; praziquantel is not the agent of choice for larval echinococcosis, which requires albendazole-based regimens and procedures.
Option E: Option E is incorrect; triclabendazole is the Fasciola agent, not the agent for echinococcosis.
6. [CASE 2 — QUESTION 2]
Continuing with the same patient. The team elects PAIR and asks how albendazole should be timed relative to the procedure. Which recommendation is correct and why?
A) Start albendazole several days before the procedure and continue it afterward, because protoscoleces spilled during puncture can seed new secondary cysts, and perioperative albendazole provides antiparasitic cover that reduces this seeding risk
B) Give albendazole only if the patient becomes symptomatic weeks after the procedure, since pre-procedure dosing is harmful
C) Administer a single albendazole dose at the moment of puncture, with no pre- or post-procedure dosing
D) Avoid albendazole entirely, since PAIR alone is curative and the drug adds no value
E) Replace PAIR with albendazole alone, since medical therapy reliably cures all active hydatid cysts
ANSWER: A
Rationale:
During puncture, viable protoscoleces can spill and seed new secondary cysts. Starting albendazole several days before the procedure establishes antiparasitic cover in advance, and continuing it afterward reduces the chance that spilled protoscoleces establish secondary disease.
Option B: Option B is incorrect; pre-procedure dosing is recommended, not harmful, and waiting for symptoms defeats the prophylactic purpose.
Option C: Option C is incorrect; a single dose at puncture without pre- and post-procedure cover is inadequate against seeding.
Option D: Option D is incorrect; PAIR alone is not reliably curative given the seeding risk, so the drug does add value.
Option E: Option E is incorrect; for active cysts the drug complements rather than replaces the procedure, so albendazole alone is not a reliable cure.
7. [CASE 2 — QUESTION 3]
Continuing with the same patient. She is placed on albendazole as part of her echinococcosis management. Which statement best characterizes how prolonged albendazole therapy for echinococcosis is conventionally administered and monitored?
A) As a single one-time dose identical to soil-transmitted nematode deworming, with no monitoring
B) As continuous lifelong therapy that never requires any laboratory monitoring
C) As a one-week course given once, after which no further dosing or follow-up is needed
D) As intermittent therapy given only on the day of any procedure, with no extended course
E) As an extended course (conventionally given in repeated multi-week cycles for cystic disease), with periodic monitoring of liver enzymes and blood counts because prolonged albendazole can cause hepatotoxicity and marrow suppression
ANSWER: E
Rationale:
Unlike single-dose deworming, echinococcosis requires an extended albendazole course (conventionally repeated multi-week cycles for cystic disease), and because prolonged albendazole can cause hepatotoxicity and bone-marrow suppression, periodic monitoring of liver enzymes and blood counts is part of safe administration.
Option A: Option A is incorrect; tissue echinococcosis is not treated with a single deworming dose, and monitoring is needed.
Option B: Option B is incorrect; while therapy is prolonged, it is monitored rather than monitoring-free, and is not necessarily lifelong for cystic disease.
Option C: Option C is incorrect; a single one-week course without follow-up is inadequate for echinococcosis.
Option D: Option D is incorrect; albendazole is given as an extended course, not only on the day of a procedure.
8. [CASE 2 — QUESTION 4]
Continuing with the same patient. For teaching, the team contrasts her cystic echinococcosis with alveolar echinococcosis caused by Echinococcus multilocularis. Which statement correctly describes alveolar echinococcosis and its management?
A) Alveolar echinococcosis is a benign, self-limited cyst that resolves without treatment
B) Alveolar echinococcosis behaves like an invasive malignancy, infiltrating tissue rather than forming a single well-defined cyst; management aims at radical surgical resection with perioperative and long-term (often indefinite) albendazole, and medically inoperable disease requires indefinite albendazole suppression
C) Alveolar echinococcosis is best treated with a single dose of praziquantel
D) Alveolar echinococcosis responds to triclabendazole, the agent of choice for all Echinococcus species
E) Alveolar echinococcosis requires only short-course diethylcarbamazine
ANSWER: B
Rationale:
Alveolar echinococcosis behaves more like an invasive malignancy than a discrete cyst, infiltrating host tissue; management targets radical surgical resection with perioperative and long-term (often indefinite) albendazole, and when disease is medically inoperable, indefinite albendazole suppression is required.
Option A: Option A is incorrect; alveolar echinococcosis is aggressive and progressive, not benign and self-limited.
Option C: Option C is incorrect; a single praziquantel dose does not treat larval alveolar echinococcosis.
Option D: Option D is incorrect; triclabendazole is the Fasciola agent, not the agent for Echinococcus.
Option E: Option E is incorrect; short-course diethylcarbamazine is a filarial regimen and has no role in alveolar echinococcosis.
9. [CASE 3 — QUESTION 1]
A 60-year-old man (C.E.) who lived for many years in rural Southeast Asia is about to start high-dose corticosteroids plus a steroid-sparing immunosuppressant for newly diagnosed pemphigus. His pre-treatment labs show eosinophilia of 1,500 cells/microliter; he has only vague intermittent abdominal symptoms. Which action is most appropriate before immunosuppression begins?
A) Proceed with immunosuppression and evaluate the eosinophilia only if symptoms worsen later
B) Treat empirically with mebendazole, the definitive agent for the dangerous occult parasite here
C) Treat empirically with praziquantel, since the dangerous occult parasite here is a fluke
D) Test for Strongyloides stercoralis and treat with ivermectin before starting immunosuppression, because corticosteroids can convert latent strongyloidiasis into a frequently fatal hyperinfection syndrome
E) Begin diethylcarbamazine empirically, the standard agent for occult tissue nematodes before immunosuppression
ANSWER: D
Rationale:
In a patient from an endemic region with unexplained eosinophilia, the dominant concern before immunosuppression is latent Strongyloides, because corticosteroids can precipitate a frequently fatal hyperinfection syndrome. Testing for Strongyloides and treating with ivermectin (the first-line agent) before starting immunosuppression is the correct step.
Option A: Option A is incorrect; waiting for worsening symptoms risks fatal hyperinfection.
Option B: Option B is incorrect; benzimidazole efficacy against Strongyloides is inferior, so mebendazole is not the definitive agent.
Option C: Option C is incorrect; Strongyloides is a nematode, not a fluke, and praziquantel does not treat it.
Option E: Option E is incorrect; diethylcarbamazine is a filarial agent and is not the agent for occult strongyloidiasis.
10. [CASE 3 — QUESTION 2]
Continuing with the same patient. Serology for Strongyloides returns positive. A trainee asks why ivermectin is chosen over a benzimidazole for definitive treatment. Which statement is correct?
A) Benzimidazoles are more effective than ivermectin against Strongyloides, so mebendazole should be used instead
B) Ivermectin is the first-line agent because it is more effective against Strongyloides than the benzimidazoles, whose efficacy against this parasite is inferior
C) Ivermectin and benzimidazoles are equally effective, so either is equally appropriate as definitive therapy
D) Praziquantel is preferred over both, since Strongyloides is a trematode
E) Diethylcarbamazine is preferred over both, since Strongyloides is a filarial nematode
ANSWER: B
Rationale:
Ivermectin is the first-line agent for strongyloidiasis because it is more effective against Strongyloides stercoralis than the benzimidazoles, whose efficacy against this parasite is inferior.
Option A: Option A inverts the efficacy relationship.
Option C: Option C is incorrect; the two are not equally effective, which is why ivermectin is preferred.
Option D: Option D is incorrect; Strongyloides is a nematode, not a trematode, so praziquantel is inappropriate.
Option E: Option E is incorrect; Strongyloides is an intestinal/tissue-migrating nematode but not a filarial worm, and diethylcarbamazine is not its treatment.
11. [CASE 3 — QUESTION 3]
Continuing with the same patient. Consider a counterfactual in which corticosteroids had been started without screening and he developed Strongyloides hyperinfection. Which feature is most characteristic of hyperinfection/disseminated strongyloidiasis and informs its management?
A) It is a purely localized skin rash with no systemic implications and needs only topical therapy
B) It reliably resolves spontaneously once steroids are continued, so antiparasitic therapy is unnecessary
C) Massive autoinfective larval migration can carry enteric gram-negative bacteria into the bloodstream and meninges, producing gram-negative bacteremia or meningitis; management requires reducing immunosuppression where possible, prolonged or repeated ivermectin, and treatment of the concurrent bacterial infection
D) It is best treated by escalating the corticosteroid dose to suppress the parasite
E) It responds only to praziquantel, since dissemination converts the nematode into a fluke-like organism
ANSWER: C
Rationale:
In hyperinfection/disseminated strongyloidiasis, massive autoinfective larval migration can carry enteric gram-negative bacteria into the bloodstream and central nervous system, producing gram-negative bacteremia or meningitis; management requires reducing immunosuppression where possible, prolonged or repeated ivermectin, and treating the concurrent bacterial infection.
Option A: Option A is incorrect; hyperinfection is a systemic, often fatal syndrome, not a localized rash.
Option B: Option B is incorrect; it does not resolve by continuing steroids, which in fact worsen it, and antiparasitic therapy is essential.
Option D: Option D is incorrect; escalating corticosteroids worsens hyperinfection rather than suppressing the parasite.
Option E: Option E is incorrect; the organism remains a nematode, and praziquantel is not its treatment.
12. [CASE 3 — QUESTION 4]
Continuing with the same patient. The team discusses how peripheral eosinophilia behaves in Strongyloides infection. Which statement is most accurate and clinically useful?
A) Eosinophilia often accompanies chronic strongyloidiasis and, in the pre-immunosuppression screening setting, its resolution after empirical antihelminthic therapy can serve as indirect evidence of a parasitic cause; however, in severe hyperinfection eosinophilia may be blunted or absent, and that absence is a poor prognostic sign rather than reassurance
B) Eosinophilia is never associated with Strongyloides at any stage, so its presence excludes the diagnosis
C) A normal eosinophil count during severe hyperinfection reliably indicates a good prognosis
D) Eosinophilia, if present, confirms bacterial superinfection rather than a parasitic process
E) Eosinophilia is a direct measure of praziquantel efficacy in strongyloidiasis
ANSWER: A
Rationale:
Chronic strongyloidiasis is commonly associated with eosinophilia, and in the pre-immunosuppression screening setting its resolution after empirical antihelminthic therapy can serve as indirect evidence of a parasitic cause; importantly, in severe hyperinfection the eosinophil count may be blunted or suppressed, and that absence is a poor prognostic sign rather than reassurance.
Option B: Option B is incorrect; eosinophilia is associated with Strongyloides, so it does not exclude the diagnosis.
Option C: Option C is incorrect; a normal count during severe hyperinfection is concerning, not reassuring.
Option D: Option D is incorrect; eosinophilia reflects the parasitic process, not bacterial superinfection.
Option E: Option E is incorrect; praziquantel does not treat Strongyloides, so eosinophilia is not a measure of its efficacy here.
13. [CASE 4 — QUESTION 1]
A 36-year-old man (B.N.) from a forest region of Central Africa has onchocerciasis (river blindness) with pruritic skin nodules and microfilariae confirmed on skin snip. He is from an area where Loa loa is also endemic. The clinic plans ivermectin for the onchocerciasis. Which step is most critical before administering the ivermectin?
A) Administer ivermectin immediately at double the standard dose to ensure macrofilarial kill, with no further workup
B) Give diethylcarbamazine instead, since it is the safest agent for onchocerciasis
C) Withhold all therapy permanently, because onchocerciasis cannot be safely treated in Loa loa-endemic regions
D) Start praziquantel, since onchocerciasis is caused by a fluke
E) Assess the patient's Loa loa microfilarial burden before giving ivermectin, because a very high Loa loa density markedly raises the risk of severe, potentially fatal encephalopathy from rapid microfilarial death
ANSWER: E
Rationale:
Ivermectin is the appropriate microfilaricidal agent for onchocerciasis, but in a Loa loa co-endemic setting the critical pre-treatment step is to assess the Loa loa microfilarial burden, because a very high Loa loa density markedly raises the risk of a severe, potentially fatal encephalopathy when large numbers of microfilariae die rapidly.
Option A: Option A is incorrect; doubling the dose without assessing Loa loa burden is dangerous, and ivermectin is not reliably macrofilaricidal.
Option B: Option B is incorrect; diethylcarbamazine is hazardous in onchocerciasis (severe Mazzotti reaction), so it is not the safe choice.
Option C: Option C is incorrect; onchocerciasis can be treated with appropriate Loa loa risk assessment, so permanent withholding is wrong.
Option D: Option D is incorrect; onchocerciasis is caused by a filarial nematode, not a fluke, so praziquantel is inappropriate.
14. [CASE 4 — QUESTION 2]
Continuing with the same patient. A trainee suggests using diethylcarbamazine for his onchocerciasis. Why is diethylcarbamazine specifically contraindicated for onchocerciasis treatment?
A) Diethylcarbamazine has no antifilarial activity whatsoever, so it would simply be ineffective
B) Diethylcarbamazine is contraindicated only because it is more expensive than ivermectin
C) Diethylcarbamazine can provoke a severe Mazzotti-type reaction in onchocerciasis from the rapid death of Onchocerca volvulus microfilariae, including the risk of ocular inflammation and worsening eye disease
D) Diethylcarbamazine is contraindicated because it is a macrofilaricidal agent too potent for skin disease
E) Diethylcarbamazine is unsafe only in patients without Loa loa co-infection
ANSWER: C
Rationale:
Diethylcarbamazine can provoke a severe Mazzotti-type reaction in onchocerciasis because it triggers rapid death of Onchocerca volvulus microfilariae, with intense inflammation that includes the risk of ocular involvement and worsening eye disease; this is why it is avoided in onchocerciasis.
Option A: Option A is incorrect; diethylcarbamazine does have antifilarial activity, so ineffectiveness is not the issue.
Option B: Option B is incorrect; the contraindication is the dangerous reaction, not cost.
Option D: Option D is incorrect; the problem is the reaction to dying microfilariae, not excessive macrofilaricidal potency.
Option E: Option E inverts the risk; the danger applies to onchocerciasis itself, and Loa loa co-infection adds a separate encephalopathy risk rather than being the only condition under which diethylcarbamazine is unsafe.
15. [CASE 4 — QUESTION 3]
Continuing with the same patient. After Loa loa risk is addressed and ivermectin is given, the patient asks whether a single dose will cure him permanently. Which explanation is correct?
A) A single ivermectin dose kills the adult worms outright, so no further treatment is ever required
B) Ivermectin is predominantly microfilaricidal and only weakly affects the long-lived adult Onchocerca worms, which survive and continue producing microfilariae; repeated annual or semi-annual dosing is therefore needed to keep microfilarial loads suppressed across the adult worms' reproductive lifespan
C) A single dose permanently sterilizes the adult worms, so microfilariae can never return
D) Repeat dosing is needed only because ivermectin is destroyed by stomach acid and never reaches the skin
E) Cure requires switching to praziquantel after the first ivermectin dose
ANSWER: B
Rationale:
Ivermectin is predominantly microfilaricidal and only weakly affects the long-lived adult Onchocerca worms, which survive and keep producing microfilariae. Because the adults persist and reproduce, microfilarial loads rebound, so repeated annual or semi-annual dosing is needed to keep microfilarial density (and the skin and eye disease it drives) suppressed across the adult worms' reproductive lifespan.
Option A: Option A is incorrect; a single dose does not kill the adult worms.
Option C: Option C is incorrect; ivermectin does not permanently sterilize the adults after one dose.
Option D: Option D is incorrect; the need for repeat dosing reflects adult-worm survival and microfilarial rebound, not acid destruction of the drug.
Option E: Option E is incorrect; praziquantel is not used for onchocerciasis.
16. [CASE 4 — QUESTION 4]
Continuing with the same patient. Over several years of community treatment, programs in some West African foci have reported suboptimal microfilarial suppression despite confirmed ivermectin dosing. Which statement best characterizes this phenomenon and the appropriate response?
A) It proves that ivermectin has never had any activity against Onchocerca, so the drug should be abandoned globally
B) It reflects universal, complete ivermectin resistance already present in all Onchocerca populations worldwide
C) It is impossible, because filarial parasites cannot develop any change in drug susceptibility
D) It reflects emerging reduced ivermectin susceptibility in localized foci after sustained mass treatment, plausibly involving glutamate-gated chloride channel changes and drug-efflux mechanisms; the appropriate response is enhanced parasitological surveillance, careful follow-up, and research into alternative and macrofilaricidal agents
E) It is fully explained by patients secretly not taking the drug, so no biological surveillance is warranted
ANSWER: D
Rationale:
Suboptimal microfilarial suppression despite confirmed dosing in certain West African foci reflects emerging reduced ivermectin susceptibility after sustained mass treatment, plausibly involving glutamate-gated chloride channel changes and drug-efflux mechanisms; the appropriate response is enhanced parasitological surveillance, careful follow-up, and research into alternative and macrofilaricidal agents.
Option A: Option A is incorrect; ivermectin has well-established microfilaricidal activity, so the finding does not negate its efficacy or warrant global abandonment.
Option B: Option B is incorrect; this is localized emerging reduced susceptibility, not universal complete resistance everywhere.
Option C: Option C is incorrect; reduced susceptibility can and does emerge under sustained drug pressure.
Option E: Option E is incorrect; while adherence matters, the signal in these foci occurs despite confirmed dosing, so biological surveillance is warranted.
17. [CASE 5 — QUESTION 1]
A 29-year-old traveler (H.G.) develops terminal hematuria and is diagnosed with urinary schistosomiasis (Schistosoma haematobium) after freshwater exposure in East Africa. He is treated with praziquantel. The team reviews how praziquantel kills the adult worms. Which description of its mechanism is correct?
A) Praziquantel increases calcium permeability of the worm tegument, causing sustained contraction and spastic paralysis, and at higher concentrations disrupts the tegument so that previously concealed surface antigens are exposed to host immune attack
B) Praziquantel binds parasite beta-tubulin and blocks microtubule assembly
C) Praziquantel opens glutamate-gated chloride channels, producing flaccid paralysis
D) Praziquantel is a nicotinic acetylcholine receptor agonist causing spastic paralysis at the neuromuscular junction
E) Praziquantel inhibits folate synthesis, halting worm DNA replication
ANSWER: A
Rationale:
Praziquantel acts on the worm tegument: it increases calcium permeability, producing sustained contraction and spastic paralysis, and at higher concentrations it disrupts the tegument so that surface antigens normally hidden from the host are exposed to immune effector attack.
Option B: Option B describes the benzimidazole mechanism.
Option C: Option C describes ivermectin, which produces flaccid paralysis via chloride channels.
Option D: Option D describes a nicotinic agonist such as pyrantel.
Option E: Option E describes antifolate drugs, which are unrelated to praziquantel.
18. [CASE 5 — QUESTION 2]
Continuing with the same patient. To maximize cure, the clinician plans a second praziquantel course several weeks after the first. What is the rationale?
A) Praziquantel induces its own metabolism, so a second dose is needed only to overcome autoinduction
B) The first dose kills the adults but leaves eggs, which the second dose then kills directly
C) Praziquantel accumulates slowly, so the second dose is required merely to reach therapeutic plasma levels
D) The second dose is needed only because the first is routinely vomited
E) Praziquantel is most active against adult worms and weakly active against immature schistosomula; worms still maturing at the first dose survive it, and a second course four to six weeks later catches them once matured into susceptible adults
ANSWER: E
Rationale:
Praziquantel is most active against adult worms and only weakly active against immature schistosomula. Worms that were still maturing at the first dose survive it, so a second course four to six weeks later catches them once they have matured into susceptible adults, raising the cure rate.
Option A: Option A is incorrect; the benefit is not about overcoming autoinduction.
Option B: Option B is incorrect; the second dose works by killing now-mature worms, not by directly killing eggs.
Option C: Option C is incorrect; the rationale is worm maturation, not slow drug accumulation.
Option D: Option D is incorrect; the second course addresses immature-stage survival, not routine vomiting.
19. [CASE 5 — QUESTION 3]
Continuing with the same patient. It emerges that he was started on rifampicin-based therapy for active tuberculosis two weeks ago. How does this affect the praziquantel plan, and why?
A) Continue standard praziquantel unchanged, since rifampicin and praziquantel do not interact
B) Reduce the praziquantel dose, because rifampicin inhibits its metabolism and would otherwise cause toxicity
C) Increase the rifampicin dose to improve praziquantel absorption and efficacy
D) Avoid giving praziquantel concurrently with rifampicin and arrange alternative timing or approach, because rifampicin potently induces CYP3A4 and sharply lowers praziquantel plasma levels, risking treatment failure
E) Switch the schistosomiasis treatment to diethylcarbamazine, which rifampicin does not affect
ANSWER: D
Rationale:
Rifampicin is a potent CYP3A4 inducer, and praziquantel undergoes extensive CYP3A4-dependent first-pass metabolism; concurrent use sharply lowers praziquantel plasma concentrations and risks treatment failure, so the appropriate action is to avoid co-administration and arrange alternative timing or approach.
Option A: Option A is incorrect; the interaction is real and clinically important.
Option B: Option B is incorrect; rifampicin induces rather than inhibits CYP3A4, so levels fall, not rise, and dose reduction worsens it.
Option C: Option C is incorrect; increasing rifampicin deepens induction and further lowers praziquantel levels.
Option E: Option E is incorrect; diethylcarbamazine is a filarial agent and does not treat schistosomiasis, so it is not a valid substitute.
20. [CASE 5 — QUESTION 4]
Continuing with the same patient. Stool and urine studies suggest a very heavy Schistosoma burden. After praziquantel, he develops more pronounced headache, malaise, abdominal pain, and low-grade fever than typically expected. Which interpretation is most accurate?
A) These symptoms prove direct praziquantel hepatotoxicity unrelated to the parasites and require immediate drug discontinuation for life
B) These symptoms indicate a bacterial superinfection and are unrelated to the schistosomes
C) Much of praziquantel's common adverse-effect profile reflects antigen release and inflammation from dying parasites, so a very heavy worm burden can produce a more pronounced systemic worm-death reaction; supportive care and monitoring are appropriate while the reaction settles
D) These symptoms mean the praziquantel was counterfeit and contained no active drug
E) These symptoms confirm that praziquantel has no effect at high worm burdens
ANSWER: C
Rationale:
Much of praziquantel's common adverse-effect profile (headache, malaise, abdominal pain, low-grade fever) reflects antigen release and inflammation as parasites die rather than direct drug toxicity; a very heavy worm burden can therefore produce a more pronounced systemic worm-death reaction, for which supportive care and monitoring are appropriate.
Option A: Option A is incorrect; these are typical worm-death-reaction symptoms, not proof of direct lifelong hepatotoxicity.
Option B: Option B is incorrect; the picture fits parasite death, not bacterial superinfection.
Option D: Option D is incorrect; the reaction is consistent with effective drug action against a heavy burden, not counterfeit drug.
Option E: Option E is incorrect; a pronounced death reaction indicates the drug is acting, not that it is ineffective.
21. [CASE 6 — QUESTION 1]
A district health officer (managing a community program) is planning mass drug administration for lymphatic filariasis in a region where onchocerciasis is NOT present. She must select the two-drug regimen. Which regimen is appropriate for a non-onchocerciasis area, and why?
A) Ivermectin plus albendazole, because diethylcarbamazine can never be used in any lymphatic filariasis program
B) Diethylcarbamazine plus albendazole, because diethylcarbamazine is appropriate where onchocerciasis is absent; the ivermectin-plus-albendazole regimen is reserved for onchocerciasis-co-endemic areas to avoid diethylcarbamazine-induced reactions to Onchocerca microfilariae
C) Praziquantel plus pyrantel, the standard lymphatic filariasis program regimen
D) Triclabendazole plus mebendazole, the preferred filariasis combination
E) Diethylcarbamazine alone, since adding albendazole provides no benefit in any setting
ANSWER: B
Rationale:
Where onchocerciasis is absent, diethylcarbamazine plus albendazole is an appropriate lymphatic filariasis mass-treatment regimen. The alternative, ivermectin plus albendazole, is reserved for onchocerciasis-co-endemic areas specifically to avoid diethylcarbamazine-induced severe reactions to dying Onchocerca microfilariae.
Option A: Option A is incorrect; diethylcarbamazine is appropriate in non-onchocerciasis areas, so the claim that it can never be used is wrong.
Option C: Option C is incorrect; praziquantel and pyrantel are not the lymphatic filariasis program regimen.
Option D: Option D is incorrect; triclabendazole and mebendazole are not the filariasis combination.
Option E: Option E is incorrect; albendazole is combined with diethylcarbamazine in mass treatment and does contribute, so diethylcarbamazine alone is not the standard.
22. [CASE 6 — QUESTION 2]
Continuing with the same patient. A neighboring district that is co-endemic for onchocerciasis is added to the campaign. Which adjustment to the lymphatic filariasis regimen is required for that district, and why?
A) Continue diethylcarbamazine plus albendazole unchanged, since onchocerciasis co-endemicity does not affect the choice
B) Switch to praziquantel plus pyrantel, which is safer where onchocerciasis is present
C) Stop all mass drug administration permanently in that district
D) Switch to ivermectin plus albendazole, because diethylcarbamazine is hazardous where onchocerciasis is co-endemic (it can trigger a severe Mazzotti reaction from rapid death of Onchocerca microfilariae, including ocular harm)
E) Use triclabendazole plus mebendazole, the preferred regimen in onchocerciasis zones
ANSWER: D
Rationale:
In a district co-endemic for onchocerciasis, the lymphatic filariasis regimen must switch to ivermectin plus albendazole because diethylcarbamazine can trigger a severe Mazzotti reaction from rapid death of Onchocerca microfilariae, including the risk of ocular harm.
Option A: Option A is incorrect; onchocerciasis co-endemicity is precisely what changes the regimen.
Option B: Option B is incorrect; praziquantel plus pyrantel is not a lymphatic filariasis regimen.
Option C: Option C is incorrect; mass treatment continues with the appropriate ivermectin-based regimen rather than stopping.
Option E: Option E is incorrect; triclabendazole and mebendazole are not the filariasis regimen.
23. [CASE 6 — QUESTION 3]
Continuing with the same patient. A community member asks why the campaign requires repeated annual rounds rather than a single mass treatment. Which explanation is most accurate?
A) The mass-treatment drugs are predominantly microfilaricidal and only weakly macrofilaricidal, so they clear circulating microfilariae but largely spare the long-lived adult worms; repeated annual rounds are needed to keep microfilarial loads (and thus transmission) suppressed over the adult worms' reproductive lifespan
B) A single round permanently kills all adult filarial worms, so repeated rounds are purely administrative
C) The drugs are macrofilaricidal but not microfilaricidal, so repeated rounds target adult worms missed earlier
D) Repeated rounds are needed only because the drugs are destroyed by sunlight during distribution
E) Annual rounds exist solely because of universal high-grade resistance in all filarial populations
ANSWER: A
Rationale:
The lymphatic filariasis mass-treatment agents are predominantly microfilaricidal and only weakly macrofilaricidal; they clear circulating microfilariae but largely spare the long-lived adult worms, which continue producing microfilariae. Repeated annual rounds are therefore needed to keep microfilarial loads and transmission suppressed across the adult worms' reproductive lifespan.
Option B: Option B is incorrect; a single round does not permanently kill all adult worms.
Option C: Option C inverts the pharmacology; the agents are microfilaricidal, not predominantly macrofilaricidal.
Option D: Option D is incorrect; the need for repeat rounds reflects parasite biology, not sunlight degradation.
Option E: Option E is incorrect; universal high-grade resistance is not the reason for routine repeat rounds.
24. [CASE 6 — QUESTION 4]
Continuing with the same patient. In the non-onchocerciasis district using diethylcarbamazine plus albendazole, the team must decide how to handle pregnant women during mass drug administration. Which approach is correct?
A) Give pregnant women the standard diethylcarbamazine-plus-albendazole regimen, since diethylcarbamazine is the safest antifilarial in pregnancy
B) Give pregnant women a double dose of diethylcarbamazine to ensure clearance
C) Give pregnant women ivermectin as the routine first-line antifilarial in any pregnancy
D) Substitute triclabendazole for pregnant women, since it is the safest filarial agent in pregnancy
E) Exclude pregnant women from the diethylcarbamazine-containing mass treatment, because diethylcarbamazine is contraindicated in pregnancy; defer their treatment until after pregnancy per program policy
ANSWER: E
Rationale:
Diethylcarbamazine is contraindicated in pregnancy, so pregnant women should be excluded from diethylcarbamazine-containing mass drug administration and their treatment deferred until after pregnancy per program policy.
Option A: Option A is incorrect; diethylcarbamazine is contraindicated, not safest, in pregnancy.
Option B: Option B is incorrect; a double dose in pregnancy is dangerous and inappropriate.
Option C: Option C is incorrect; ivermectin has limited pregnancy safety data and is generally avoided except in life-threatening disease, so it is not a routine first-line antifilarial in pregnancy.
Option D: Option D is incorrect; triclabendazole is the Fasciola agent, not an antifilarial, and is not the pregnancy substitute here.
25. [CASE 7 — QUESTION 1]
A 27-year-old woman (F.A.), 24 weeks pregnant, lives in a high-prevalence region and is found to have a mixed soil-transmitted helminth burden (Ascaris and hookworm) contributing to anemia. The team must choose initial therapy. Which approach is most appropriate?
A) Defer all treatment until after delivery, since every antihelminthic is absolutely contraindicated throughout pregnancy
B) Use diethylcarbamazine, the preferred antihelminthic in pregnancy
C) Give a single dose of a benzimidazole (albendazole or mebendazole), which is used for soil-transmitted helminthiasis from the second trimester onward in high-prevalence settings, because treating a significant burden contributing to anemia is a net benefit in pregnancy
D) Use routine ivermectin as the first-line agent for these nematodes in any pregnancy
E) Use triclabendazole, the safest soil-transmitted nematode agent in pregnancy
ANSWER: C
Rationale:
A significant soil-transmitted helminth burden contributing to anemia warrants treatment in pregnancy, and a single dose of albendazole or mebendazole is used for soil-transmitted helminthiasis from the second trimester onward in high-prevalence settings; at 24 weeks she is in the second trimester.
Option A: Option A is incorrect; treating a significant burden from the second trimester is beneficial, so blanket deferral is wrong.
Option B: Option B is incorrect; diethylcarbamazine is contraindicated in pregnancy and is a filarial agent, not a treatment for soil-transmitted nematodes.
Option D: Option D is incorrect; ivermectin has limited pregnancy safety data and is generally avoided except in life-threatening disease.
Option E: Option E is incorrect; triclabendazole is the Fasciola agent, not a soil-transmitted nematode treatment.
26. [CASE 7 — QUESTION 2]
Continuing with the same patient. The team considers pyrantel pamoate as an alternative for the Ascaris and hookworm. Which statement correctly pairs pyrantel's mechanism with the property that makes it acceptable in pregnancy?
A) Pyrantel is a depolarizing nicotinic acetylcholine receptor agonist causing spastic paralysis of the worm; it is very poorly absorbed and therefore largely confined to the gut lumen, and this minimal systemic exposure underlies its acceptability in pregnancy
B) Pyrantel is a glutamate-gated chloride channel opener causing flaccid paralysis, and it is acceptable in pregnancy because it is fully systemically absorbed
C) Pyrantel binds beta-tubulin and is acceptable in pregnancy because it crosses the placenta freely
D) Pyrantel increases tegument calcium permeability like praziquantel and is acceptable in pregnancy because it is macrofilaricidal
E) Pyrantel inhibits folate synthesis and is acceptable in pregnancy because it concentrates in fetal tissue
ANSWER: A
Rationale:
Pyrantel is a depolarizing nicotinic acetylcholine receptor agonist that produces spastic paralysis of the worm; because it is very poorly absorbed and largely confined to the gut lumen, systemic (and fetal) exposure is minimal, which underlies its acceptability in pregnancy.
Option B: Option B is incorrect; pyrantel causes spastic, not flaccid, paralysis, is not a chloride-channel opener, and is not fully absorbed.
Option C: Option C is incorrect; pyrantel does not bind beta-tubulin, and free placental crossing would be undesirable, not reassuring.
Option D: Option D is incorrect; pyrantel does not act like praziquantel and is not macrofilaricidal.
Option E: Option E is incorrect; pyrantel is not an antifolate, and fetal-tissue concentration would be a hazard rather than a basis for safety.
27. [CASE 7 — QUESTION 3]
Continuing with the same patient. Suppose follow-up stool studies also reveal Trichuris trichiura (whipworm). How does this finding affect the choice between pyrantel and a benzimidazole?
A) It makes no difference, because pyrantel reliably clears Trichuris just as it clears Ascaris and hookworm
B) It mandates switching to diethylcarbamazine, the agent of choice for whipworm
C) It mandates praziquantel, since Trichuris is a trematode
D) It mandates triclabendazole, since Trichuris requires the Fasciola agent
E) It favors a benzimidazole, because pyrantel is NOT reliably active against Trichuris trichiura, whereas a benzimidazole covers Trichuris along with Ascaris and hookworm
ANSWER: E
Rationale:
Pyrantel is active against Ascaris, hookworm, and Enterobius but is not reliably active against Trichuris trichiura. If whipworm is also present, a benzimidazole is favored because it covers Trichuris in addition to Ascaris and hookworm.
Option A: Option A is incorrect; pyrantel does not reliably clear Trichuris, which is the entire point of the distinction.
Option B: Option B is incorrect; diethylcarbamazine is a filarial agent and is not the agent of choice for whipworm.
Option C: Option C is incorrect; Trichuris is a nematode, not a trematode, so praziquantel is inappropriate.
Option D: Option D is incorrect; triclabendazole is the Fasciola agent and is not used for whipworm.
28. [CASE 7 — QUESTION 4]
Continuing with the same patient. A colleague proposes adding piperazine to pyrantel to "cover more worms." Recalling that piperazine produces hyperpolarizing (flaccid) paralysis, what is the correct assessment of combining it with pyrantel?
A) The combination is ideal and synergistic, since both drugs paralyze the worm by the same mechanism
B) The combination should be avoided because the two drugs are pharmacologically antagonistic: pyrantel produces depolarizing spastic paralysis while piperazine produces hyperpolarizing flaccid paralysis, so their opposing effects counteract each other
C) The combination is required for hookworm, since neither drug works alone
D) Piperazine converts pyrantel into a more potent spastic agent, enhancing efficacy
E) The two drugs do not interact at all because they act on entirely separate organ systems in the worm
ANSWER: B
Rationale:
Pyrantel produces depolarizing spastic paralysis, whereas piperazine produces hyperpolarizing flaccid paralysis; because these effects on the worm's membrane potential oppose one another, the drugs are pharmacologically antagonistic and the combination should be avoided.
Option A: Option A is incorrect; the drugs act by opposite mechanisms, so they are antagonistic rather than synergistic.
Option C: Option C is incorrect; pyrantel alone is effective against hookworm, so the combination is not required.
Option D: Option D is incorrect; piperazine does not convert pyrantel into a more potent spastic agent.
Option E: Option E is incorrect; both drugs act on the worm neuromuscular system, so they do interact, and the interaction is antagonistic.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.